Vivanta Industries Ltd

Vivanta Industries Ltd has issued a confirmation regarding its fundraising activities. Pursuant to SEBI regulations and a circular dated December 24, 2019, the company states that it has not raised any funds through Public Issue, Rights Issue, Preferential Issue, or Qualified Institutions Placement (QIP) etc. Consequently, a Statement of Deviation or Variation is not being provided as it is not applicable to the company. This filing serves as a record of their current fundraising status.

Vivanta Industries Ltd announced that its Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also noted disclosures of interest received from directors, declarations of independence from independent directors, and the issuance of a duplicate share certificate. Additionally, the company took note of business collaboration agreements with Qness Pharmaceuticals, the Corporate Governance Report for Q1 FY27, and the e-form DPT-3 for the financial year ended March 31, 2026. Authorizations for opening trading and demat accounts and for signing statutory documents were also approved.

Vivanta Industries Ltd announced that its Board of Directors has approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The approval also includes year-to-date figures for the period from April 1, 2026, to June 30, 2026. The board meeting also noted disclosures of interest from directors, declarations from independent directors, issuance of duplicate share certificates, business collaboration agreements with Qness Pharmaceuticals, corporate governance report, e-form DPT-3, and authorization for opening trading and demat accounts. Designated signatories were authorized to file statutory forms.

Vivanta Industries Ltd has rescheduled its Board of Directors meeting from July 24, 2026, to July 29, 2026, due to heavy rainfall. The meeting will inter alia consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. Additionally, the board will authorize signatories for audited financial statements for the year ended March 31, 2026, take note of duplicate share certificates, a business collaboration with Qness Pharmaceuticals, the Corporate Governance Report, and the E-Form DPT-3 Return of Deposits for Q1 FY27. The trading window remains closed until 48 hours after the financial results declaration.

Vivanta Industries Ltd has announced a Board of Directors meeting scheduled for July 24, 2026. The meeting will primarily focus on considering and approving the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. Additionally, the board will authorize signatories for financial statements for the year ended March 31, 2026, take note of duplicate share certificates issued, a business collaboration agreement with Qness Pharmaceuticals, the Corporate Governance Report, and the E-Form DPT-3 Return of Deposits for the quarter. The trading window for designated persons remains closed until 48 hours after the financial results declaration.

Vivanta Industries Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from Wednesday, July 1st, 2026, and will remain in effect until 48 hours after the declaration of its standalone and consolidated financial results for the quarter ended June 30th, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. Promoters, directors, KMPs, designated persons, connected persons, and their immediate relatives are prohibited from trading during this period. The date of the board meeting to approve these financial results will be announced separately.

Vivanta Industries Limited has entered into business collaboration agreements with Qness Pharmaceuticals for the manufacture, supply, branding, and marketing of pharmaceutical and allied products. The collaboration is domestic and does not involve any joint venture or share exchange. No upfront consideration has been paid or received, with commercial terms to be determined by individual purchase orders. The agreements aim to strengthen Vivanta's position in the pharmaceutical sector, expand its product portfolio, enhance market reach, and create opportunities through contract manufacturing. Qness Pharmaceuticals is a proprietorship concern and not a related party to Vivanta Industries.

Vivanta Industries Limited's Board of Directors has approved the adoption of Electric Vehicle (EV) Charging Infrastructure and allied energy solutions as a new line of business. This strategic move aims to diversify revenue streams and participate in a rapidly growing, future-oriented industry driven by government initiatives and increasing EV adoption. The company expects to strengthen its position in sustainable and green energy initiatives, creating long-term value for stakeholders. Investments in this segment will be made in a phased manner, determined by business requirements, market opportunities, and feasibility assessments.

Vivanta Industries Limited's Board of Directors, at its meeting on May 28, 2026, approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The Board also approved the adoption of a new line of business: Electric Vehicle (EV) Charging Infrastructure and allied energy solutions. Additionally, M/s. Dharti Shah & Co. was appointed as the Internal Auditor for FY2026-27, and CS Devang Shah was appointed as the Nodal Officer for the Investor Education and Protection Fund (IEPF). The Board also approved the issue of duplicate share certificates.

Vivanta Industries Limited's Board of Directors approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The Board also approved the adoption of Electric Vehicle (EV) Charging Infrastructure as a new line of business, aligning with the company's strategy to explore sustainable and high-growth opportunities. Additionally, M/s. Dharti Shah & Co. was appointed as the Internal Auditor for FY 2026-2027, and CS Devang Shah was appointed as the Nodal Officer for IEPF compliance. The Board also approved the issuance of duplicate share certificates in lieu of lost ones.